AVANIR (AVNR) Higher As Phase III Trial Meets Efficacy Endpoint
More News related to AVNR
- AVANIR to Present at the Piper Jaffray Health Care Conference
- AVANIR Pharma (AVNR) Posts Q4 Loss of 9c, Wider than Anticipated
- AVANIR Pharmaceuticals Announces Fiscal 2009 Fourth Quarter and Full Year Financial Results
- Trading Radar for 11/24: Heinz (HNZ), Dollar Tree (DLTR), Eaton Vance (EV), Hormel Foods (HRL), J. Crew (JCG) Report
- AVANIR Pharmaceuticals Invites Investors to Fourth Quarter and Fiscal Year End Conference Call
More News related to FDA
- Keefe, Bruyette & Woods Downgrades First State Bancorporation (FSNM) to Market Perform
- Keefe, Bruyette & Woods Downgrades R&G Financial (RGFC) to Market Perform
AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) is seeing upside action today after the company announced detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia compared to placebo in the treatment of pseudobulbar affect (PBA) in patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS).
Over the course of the 12-week study, Zenvia 30/10 mg and 20/10 mg met the primary efficacy endpoint by reducing PBA episode rates by an incremental 47.2% and 47.8% respectively, beyond placebo (p<0.0001).
Shares of AVNR are up 11% currently.
More from Release
Related Categories
FDAMomentum Movers
Stocks Mentioned
-0.04Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
